drugset / Trial / NCT02079805

A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R

NCT02079805

Phase 4 Completed 33 enrolled Takeda
RandomizedParallel-groupOpen-labelTreatment

Summary

Multicenter, randomized, open-label, parallel-group exploratory study to explore the effects of azilsartan (Azirva), compared with telmisartan, on insulin resistance in participants with essential hypertension complicated by type 2 diabetes mellitus

Timeline

Start
2014-06
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Azilsartan Unknown 20 mg Oral
Comparator Telmisartan Other / unclassified 40 mg Oral